-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Persistent thrombocytopenia (PT) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which has a significant negative impact on survival
Persistent thrombocytopenia (PT) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which has a significant negative impact on survival
Here, a foreign research team conducted a retrospective study to evaluate the efficacy and safety of Eltrombopag (EPAG) in 34 patients with PT after allogeneic hematopoietic stem cell transplantation
Here, a foreign research team conducted a retrospective study to evaluate the efficacy and safety of Eltrombopag (EPAG) in 34 patients with PT after allogeneic hematopoietic stem cell transplantation
Seven patients had long-term solitary thrombocytopenia (PIT), and 27 patients experienced secondary platelet recovery failure (SFPR)
Figure 1: a, the cumulative incidence of overall remission (72.
Figure 2: Median platelet count after drug withdrawal and one month after drug withdrawal (P=0.
Figure 2: Median platelet count (P=0.
The cumulative incidence (CI) of platelets without transfusion support to at least 20×109×/L and 50×109/L were 72.
The cumulative incidence (CI) of platelets without transfusion support to at least 20×109×/L and 50×109/L were 72.
Figure 3: a, the cumulative incidence of total remission (P=0.
Original source:
Yan, F.
Yan, F.
, Lu, N.
, Gu, Z.
et al.
Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience.
Ann Hematol(2021).
https:// doi.
org/10.
1007/s00277-021-04706-6
leave a message here
